EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.
Issue link: https://digital.eyeworld.org/i/932603
49 EW REFRACTIVE February 2018 time. Near vision J3, J2 was achieved in 100% of the patients by the third month of treatment, and J1 was achieved in 67% by the third month. "Near visual acuity regresses at about 8 hours following drop application. The measurable im- provement in near vision decreases at about 10 hours after drops are given," Dr. Vejarano said. Scheimpflug photography demonstrated decreased anterior chamber depth as well as anteri- or displacement of the lens. UBM corroborated the decreased anterior chamber depth as well as an increase in the length and thickness of the lens. A satisfaction survey showed that in terms of near vision correc- tion for normal everyday activities, 43.75% of the patients were specta- cle independent after the first week. This increased steadily to 100% satisfaction by the second and third months post-drop. "I have been using these drops for 7 years, twice a day in presbyopic patients," Dr. Vejarano said. "In 2013 my amplitude of accommoda- tion was 1.75 D, in 2015 it was 2.50 D, and in 2017 it was more than 3.5 D. The accommodation range is making these eyes younger." FOV Tears FOV Tears is a patent pending eye drop combination that uses a para- sympathetic agent, an NSAID, two alpha agonists, and an anticholin- esterase agent to stimulate the iris and ciliary muscles, and promises to minimize the drawbacks associated with a purely parasympathetic ap- proach. The drops are given bilater- ally to avoid the scotopic disadvan- tages seen with monovision. "The treatment stimulates the contraction of the ciliary body and maintains a physiological pupil diameter variation. In this context, binocular vision avoids worsening of visual performance in reduced light and allows physiological image merging with clear focus at near, intermediate, and distance," Dr. Vejarano said. EW Reference 1. Renna A, et al. Pharmacological treatment of presbyopia by novel binocularly instilled eye drops: A pilot study. Ophthalmol Ther. 2016;5:63–73. Editors' note: Dr. Vejarano has finan- cial interests with FOV Tears. Contact information Vejarano: felipev@fov.com.com